MPM PDT Phase II Trial

Inclusion Criteria:

- Patients with a histologic diagnosis of MPM, epithelioid subtype, who in the opinion
of the attending thoracic surgeon can receive a macroscopically complete resection of
tumor.

- Patients must have disease limited to the hemithorax.

- Patients who have received prior surgery, gene therapy, or combination chemotherapy
will be permitted if it has been at least 30 days since the last treatment.

- Subjects treated with pemetrexed previously will be eligible only if 8 weeks have
elapsed between the last dose of pemetrexed and the date of surgery.

- ECOG performance status of 0-1. Medical suitability for resection,including
documented medical and cardiac clearance.

- 18 years of age or older. Patients must sign a document that indicates that they are
aware of the investigative nature of the treatment of this protocol, and the
potential benefits and risks.

- Patients unwilling or unable due to cognitive impairment to sign informed consent are
excluded from the study.

Exclusion Criteria:

- Patients with active invasive cancers, other than MPM, that require additional
treatment, except nonmelanomatous skin cancer, superficial bladder or cervical
cancer, and early-stage prostate cancer.

- Pregnant or lactating patients. Patients who have a history of HIV disease. -
Patients who have a white count less than 2,500 per cubic mm or platelets less than
100,000/cubic mm. Serum creatinine equal or greater than 2.5 mg/deciliter. -

- Patients who have severe liver disease including cirrhosis, Grade III-IV elevations
in liver function studies, or bilirubin in excess of 1.5 mg/deciliter. -

- Patients with porphyria or hypersensitivity to porphyrin or porphyrin-like compounds.

- Patients who have been treated with pemetrexed if the last dose of pemetrexed is 8
weeks to the date of surgery. -

- Patients that have been treated with prior Mantle field radiation. Patients with
distant metastatic disease or otherwise not confined to the ipsilateral hemithorax.